Dr. McGuire is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1250 E Marshall St
Dept of Imhematologyoncology
Richmond, VA 23298Phone+1 804-828-7999Fax+1 804-828-5566
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1973 - 1976
Yale-New Haven Medical CenterResidency, Internal Medicine, 1971 - 1973
Baylor College of MedicineClass of 1971
Certifications & Licensure
VA State Medical License 2012 - 2026
TX State Medical License 1971 - 2014
MD State Medical License 1974 - 2013
IL State Medical License 1979 - 1987
CT State Medical License 1972 - 1979
DC State Medical License 1976 - 1977- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Start of enrollment: 2000 Jul 01
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Jan 01
Publications & Presentations
PubMed
- 502 citationsThe effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma.William J. Hoskins, William P. McGuire, Mark F. Brady, Howard D. Homesley, William T. Creasman
American Journal of Obstetrics and Gynecology. 1994-04-01 - 648 citationsPrognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group StudyWilliam E. Winter, G. Larry Maxwell, Chunqiao Tian, Jay W. Carlson, Robert F. Ozols
Journal of Clinical Oncology. 2007-08-20 - 2146 citationsCyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian CancerWilliam P. McGuire, William J. Hoskins, Mark F. Brady, Paul R. Kucera, Edward E. Partridge
The New England Journal of Medicine. 1996-01-04
Press Mentions
First Patient Enrolled in OncoQuest's Phase 1/2 Study Combining Oregovomab with Hiltonol® in Recurrent Ovarian CancerJuly 26th, 2017
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
